2022
Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes
Potashman M, Mize M, Beiner M, Pierce S, Coric V, Schmahmann J. Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes. The Cerebellum 2022, 22: 1257-1273. PMID: 36495470, PMCID: PMC10657309, DOI: 10.1007/s12311-022-01494-1.Peer-Reviewed Original ResearchConceptsClinical outcome assessmentPatient reported symptomsImpact of illnessPatient experienceAtaxia Rating ScaleReported symptomsRating ScaleAtaxia patientsPatients/familiesMuscle discomfortMotor syndromeCerebellar motor syndromeClinician assessmentOutcome measuresClinical measuresInvoluntary movementsPatientsOutcome assessmentCerebellar ataxiaSymptomsVision impairmentMuscle controlAtaxiaHand coordinationReal-life impactRimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study
L’Italien G, Popoff E, Johnston K, McGrath D, Conway C, Powell L, Harris L, Kowalczyk N, Croop R, Coric V. Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study. Cephalalgia Reports 2022, 5: 25158163221075596. DOI: 10.1177/25158163221075596.Peer-Reviewed Original ResearchMonthly migraine daysBaseline monthly migraine daysAcute treatmentMigraine daysMedian timeMigraine frequencyOral calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistOpen-label safety studyBaseline migraine frequencyCGRP receptor blockadeOpen-label studyPeptide receptor antagonistMMD reductionReceptor blockadeMigraine attacksReceptor antagonistPreventive treatmentOutcome measuresResponse rateMigraineSafety studiesTreatmentStudy objectiveSignificant reduction
2009
Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.
Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder. Innov Clin Neurosci 2009, 6: 26-31. PMID: 19724740, PMCID: PMC2719443.Peer-Reviewed Original ResearchClinical trialsHAM-D itemsGeneralized anxiety disorderSheehan Suicidality Tracking ScaleSuicidal thoughtsWeek 8Suicidal ideationCorticotropin-releasing factor antagonistAnxiety disordersTreatment-emergent suicidal ideationActive comparator studiesExploratory outcome measuresClinician-Administered Rating ScaleMulticenter clinical trialStudy time pointsScale total scoreLarger study sampleComparator studiesStudy protocolMean changeOutcome measuresWeek 4Prospective assessmentFactor antagonistsClinical care
2007
Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania
Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania. Biological Psychiatry 2007, 62: 839-846. PMID: 17727824, DOI: 10.1016/j.biopsych.2007.05.019.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsHabit reversal therapyTreatment of trichotillomaniaCochrane Central RegisterPrimary outcome measureClinical rating scalesNon-specific effectsSSRI pharmacotherapyCentral RegisterControlled TrialsRelevant trialsReuptake inhibitorsTreat analysisPharmacotherapy studiesBlinded assessmentClinical trialsTrichotillomania severityMean changeOutcome measuresFuture therapiesElectronic databasesLarger sample sizeRigorous control conditionsPsychiatric conditionsSystematic review